We used two neuroblastoma cell lines to compare crizotinib and ceritinib treatment in a dose‐dependent and time‐dependent manner using the total ALK, pY ALK, pY1278, pY1604, and pY1586 ALK immunoassays (Fig. 3). The gene discussed is ALK; the disease is neuroblastoma.